 G1 Therapeutics, Inc. Nasdaq: GTHX and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in small cell lung cancer SCLC, with the Boehringer Ingelheim oncology commercial team, well-established in lung cancer, leading sales force engagement initiatives. 